New safety label for naproxen not justified, yet.

The FDA has rejected calls for naproxen to get a higher safety rating than other NSAIDS, and instead are awaiting the results of further research.

The calls for a change to the safety warnings comes on the back of a meta-analysis published in the Lancet last year that suggested naproxen carried a lower cardiovascular risk than other NSAIDS. 

But an FDA advisory panel voted that naproxen should not get a new label based on this data alone. 

Instead they recommend leaving the current labelling as is until data from the large Precision trial is available.